Benjamin Oakes, Scribe Therapeutics CEO
Lilly’s Prevail taps Jennifer Doudna's spinout Scribe Therapeutics for neuro genetic medicines
Scribe Therapeutics found another partner, this time with Prevail Therapeutics, a subsidiary of Eli Lilly, in a $75 million upfront deal for neuromuscular and neurological diseases.
Unlike Scribe’s ex vivo NK cell therapy partnership with Sanofi that was announced last fall, the Prevail pact is on exclusive terms for Scribe’s in vivo “CRISPR by Design” technology. Scribe also has a collaboration with Biogen on gene therapy for ALS.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters